🚨 AG1 is a scam? 🚨 They just completed a clinical trial and the results sho...
By Jonelder · January 29, 2026 · Curated by George's Blog
🚨 AG1 is a scam? 🚨
They just completed a clinical trial and the results show no clinical benefit.
Zero benefit. Nada. Zilch!
Influencers have made a killing promoting this stuff.
Two simple alternatives (75% and 56% less $), outperform AG1 in randomized clinical trials.
Two simple mono-ingredient alternatives that outperform AG1:
1. Chicory inulin 12 g daily ($20/mo)
2. Resistant starch 30 g daily for 12 weeks ($35/mo)
AG1 is not worth $79/mo.
AG1 study results (4-weeks, N=30):
+ No significant changes in blood biomarkers compared to placebo (CBC, CMP, lipids).
+ No statistically significant improvement in digestive quality-of-life scores (p = 0.058).
+ No significant metabolic or inflammatory biomarker benefits of any kind within the scope of what was measured in the trial.
+ Only small shifts in microbiome taxa but clinically irrelevant at this stage.
+ The intervention did not increase microbiome diversity compared to placebo. Alpha diversity was unchanged, and the taxa changes seen were only from pre- to post-analysis within each group. Between-group differences were limited, and the placebo actually showed similar or even potentially larger shifts. This means the observed changes fall within normal placebo-driven variability, not a real treatment effect. No global microbiota shifts were detected.
Chicory inulin 12 g in constipation patients
+ 12 g of chicory inulin daily for 4 weeks (compared to maltodextrin placebo)
+ Global microbiota shifts: enrichment in butyrate-producing Bifidobacterium and Anaerostipes, and depletion of the pro-inflammatory Bilophila.
+The effect was seen by comparing intervention vs placebo in a cross-over setting, a very rigorous type of clinical analysis in which each person serves as their own control, eliminating a lot of individual random noise.
+ The trial also met its primary objective by improving constipation symptoms in the targeted patient group.
Resistant starch daily 30g for 12 weeks in older adults
+ Significant increase in Bifidobacterium in both middle-aged and elderly participants, with an increase in the beneficial microbiome byproduct butyrate, and reductions in Proteobacteria (including inflammatory Escherichia–Shigella) in the elderly.
+ Resistant starch also significantly reduced blood glucose, and produced greater reductions in blood insulin and insulin resistance (HOMA-IR) in the elderly group.